Chimeric Therapeutics enters research agreement to further NK cell therapy portfolio
CWRU will work closely with Chimeric to advance multiple next-generation NK cell products through preclinical development.
Company
Chimeric Therapeutics Ltd
ASX:CHM
Chimeric Therapeutics Ltd, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. The company's world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of today's most innovative solutions, and has shown a consistent ability to deliver on its objectives.
83 stories · page 2 of 5
Chimeric Therapeutics appoints clinical expert Dr Stephanie Astrow VP of translational sciences
“Dr [Stephanie] Astrow has extensive experience in the development of translational strategies for solid tumour and hematologic malignancies for adoptive cell therapies in both autologous and allogeneic settings," said CEO and MD Jennifer C
Chimeric Therapeutics granted Japanese patent covering applications of CLTX CAR technology
“We are delighted to have patent protection granted for CLTX CAR therapies in Japan, the third largest pharmaceutical market in the world,” CEO and MD Jennifer Chow said.
Chimeric Therapeutics appoints cell therapy industry leader as chief medical officer
Dr Jason B Litten brings almost 15 years of leadership in drug development with the past five years dedicated to advancing NK and CAR T cell therapy clinical-stage programs in oncology.
Chimeric Therapeutics strengthens management team with experienced clinical operations executive appointed vice president
“We are excited to welcome Cassandra as vice president Clinical Operations at Chimeric, a newly created but critically important position within our organisation,” said MD Jennifer Chow.
FIVE at FIVE AU: Energy stocks rise as ASX falls and Shell cops a please explain from unions over “choking” off gas supply
Here’s Proactive Australia’s round-up of the top local financial stories of the day, with helpful links taking you directly to the news.
Chimeric Therapeutics licenses viral vector technology from University of Pennsylvania for CDH17 CAR T program
The company has acquired a licence for the University of Pennsylvania's entiviral vector plasmid system, a viral vector technology critical for the manufacture of one of the company's main platforms - chimeric antigen receptor (CAR) T cells
Chimeric Therapeutics’ CORE NK platform features in clinical first trial combining IL-2 and Vactosertib
“With the initial positive results seen in the Phase 1A clinical trial with our CORE NK Platform cells, we have been eager to accelerate the development opportunities for it,” said Chimeric CEO Jennifer Chow.
Chimeric Therapeutics achieves key development milestone
“This marks a major milestone for advancing the development of CHM 1101,” says Chimeric CEO and managing director Jennifer Chow.
Chimeric Therapeutics signs A$30 million equity placement agreement with L1 Capital
The agreement comprises an initial share placement of A$5 million and up to an additional A$30 million in share placements over a 24-month period.
Chimeric Therapeutics takes first regulatory step towards IND for cancer drug CHM 2101
“We believe that CHM 2101 offers great promise for patients with gastrointestinal cancers and are very eager to move this asset to the clinic,” says MD.
Chimeric Therapeutics exercises exclusive option for CORE-NK platform
Chimeric expects to use the CORE-NK platform while leveraging its existing portfolio of CARs to pursue new clinical trials in blood cancers and solid tumours beginning in 2023.
Chimeric Therapeutics enters manufacturing partnership with Wuxi ATU to advance cancer pipeline
The new partnership will enable the company to accelerate clinical manufacturing readiness for new CAR T assets and to scale CAR T manufacturing to support multiple, simultaneous, multicenter CAR T clinical trials in the future.
Chimeric Therapeutics' CDH17 CAR-T preclinical trials published in Nature Cancer journal
In eight different in vivo models, including colorectal cancer, gastric cancer, pancreatic cancer and neuroendocrine tumours, the preclinical data demonstrate efficacy with minimal toxicity.
Chimeric Therapeutics concludes safety trial for blood and solid tumour cancer treatment; one patient in remission
The company’s CORE NK cell platform demonstrates "safety, substantial efficacy and robust expansion and persistence of universal donor NK cells".
Chimeric Therapeutics makes a match with Be The Match BioTherapies
“We have a shared commitment to advance next-generation cell therapies for waiting patients, and we intend to help them achieve their targets,” says Be The Match.
Chimeric Therapeutics’ rights issue will provide a longer runway to data readout: Diamond Equity Research
The company has opened the retail component of its rights offer, after raising about $7.37 million from the institutional component.
Chimeric Therapeutics opens retail component of ~$18 million rights issue
Proceeds from the rights issue will be used to continue advancement of Chimeric’s cell therapy development program which is expected to see the company with four Phase 1 clinical trials within the next 12 months.
Chimeric Therapeutics initiates third dose level of the CLTX CAR T Phase 1 trial for cancer patients
“With the encouraging safety and activity signs shown in the lower two dose levels we are excited to be advancing to the higher dose levels that may provide more therapeutic benefit to patients with progressive or recurrent glioblastoma,” s
Chimeric Therapeutics raises $7.37 million, with $10.75 million still to come from retail investors
The Retail Entitlement Offer is expected to raise approximately $10.75 million and will open on February 28 and close at 5pm on March 11.